Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

Neal D. Shore

START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC

Murilo de Almeida Luz

Division of Urologic Oncology, Erasto Gaertner Hospital, Curitiba, Brazil

Ugo De Giorgi

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy

Martin Gleave

Vancouver Prostate Centre

Geoffrey T. Gotto

Southern Alberta Institute of Urology, University of Calgary, Calgary, Canada

Christopher M. Pieczonka

Clinical Research, U.S. Urology Partners and Associated Medical Professionals of New York, Syracuse

Gabriel P. Haas

Oncology Global Development, Astellas Pharma, Northbrook, IL

Choung-Soo Kim

Department of Urology, Ewha Womans University Mokdong Hospital, Seoul, South Korea

Miguel Ramirez-Backhaus

Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain

Antti Rannikko

Department of Urology and Research Program in Systems Oncology, University of Helsinki, Helsinki

Matko Kalac

Oncology Division, Pfizer, New York

Swetha Sridharan

Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia

Matt Rosales

Oncology Global Development, Astellas Pharma, Northbrook, IL

Yiyun Tang

Oncology Division, Pfizer, South San Francisco, CA

Ronald F. Tutrone

Chesapeake Urology Research Associates, Towson, MD

Balaji Venugopal

Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Arnauld Villers

Department of Urology, University of Lille, Claude Huriez Hospital, Centre Hospitalier Universitaire Lille, Lille, France

Henry H. Woo

Department of Urology, Blacktown and Mount Druitt Hospitals, Blacktown, NSW, Australia

Fong Wang

Pfizer, South San Francisco, CA

Stephen J. Freedland

Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars–Sinai Medical Center, Los Angeles